Skip to main content

Advertisement

SpringerLink
Log in

Current Drug Therapy for Parkinson’s Disease

A Review

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The impact of neuropharmacology has been greatest in 2 areas of clinical treatment: epilepsy and Parkinson’s disease. This article covers the drug treatment of Parkinson’s disease, a condition which characteristically affects the elderly population.

The 5 drugs or groups of drugs used in the treatment of Parkinson’s disease are: (a) anticholinergic drugs; (b) amantadine; (c) levodopa plus a peripheral decarboxylase inhibitor; (d) dopamine agonists; and (e) selegiline. Levodopa is still the most effective anti-Parkinsonian drug for most patients and is often combined with selegiline which may retard the rate of disease progression. The early use of dopamine agonists (such as bromocriptine) may prevent the subsequent development of response fluctuations. Once fluctuations have developed, they may be helped by the use of slow release levodopa preparations and, in the most severe cases, subcutaneous apomorphine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles, news and stories from top researchers in related subjects.

References

  • Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson’s disease. In Marsden CD & Fahn S (Eds) Movement disorders 2, pp. 166–230, Butterworth, London, 1987

    Google Scholar 

  • Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. New England Journal of Medicine 324: 746–754, 1991

    Article  PubMed  CAS  Google Scholar 

  • Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson’s disease: a long-term study. Journal of Neural Transmission 64: 113–127, 1985

    Article  PubMed  CAS  Google Scholar 

  • Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone: a review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 24: 360–400, 1982

    Article  PubMed  CAS  Google Scholar 

  • Burns BD, Dejong D, Solis-Quiroga OH. Effects of trihexyphenidyl hydrochloride (Artane) on Parkinson’s disease. Neurology 14: 13–23, 1964

    Article  PubMed  CAS  Google Scholar 

  • Cedarbaum JM. The promise and limitations of controlled-release oral levodopa administration. Clinical Neuropharmacology 12: 147–166, 1989

    Article  PubMed  CAS  Google Scholar 

  • Cedarbaum JM, Breck L, Kutt H, McDowell FH. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson’s disease. Neurology 37: 1607–1612, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Cedarbaum JM, Hoey M, Kutt H, McDowell FH. Results of long-term treatment with controlled-release levodopa/carbidopa. Annals of Neurology 22: 145, 1987b

    Google Scholar 

  • Cedarbaum JM, Hoey M, McDowell FH. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson’s disease and fluctuating motor performance. Journal of Neurology, Neurosurgery and Psychiatry 52: 207–212, 1989

    Article  CAS  Google Scholar 

  • Chrisp P, Mammen GJ, Sorkin EM. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson’s disease. Drugs & Aging 1: 228–248, 1991

    Article  CAS  Google Scholar 

  • Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of Parkinsonism. New England Journal of Medicine 276: 374–379, 1967

    Article  PubMed  CAS  Google Scholar 

  • Csanda E, Tarczy M. Selegiline in the early and late phases of Parkinson’s disease. Journal of Neural Transmission (Suppl.) 25: 105–113, 1987

    PubMed  CAS  Google Scholar 

  • Dallos V, Heathfield K, Stone P, Allen F. Comparative value of amantadine and levodopa in Parkinson’s disease. Postgraduate Medical Journal 48: 354–358, 1972

    Article  PubMed  CAS  Google Scholar 

  • Duvoisin RC. Cholinergic-anticholinergic antagonism in parkinsonism. Archives of Neurology 17: 124–136, 1967

    Article  PubMed  CAS  Google Scholar 

  • Erni W, Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. European Neurology 27(Suppl. 1): 21–27, 1987

    Article  PubMed  CAS  Google Scholar 

  • Feldberg W. Present views on the mode of action of acetylcholine in the central nervous system. Physiological Reviews 25: 596–642, 1945

    PubMed  CAS  Google Scholar 

  • Forno LS. Pathology of Parkinson’s disease: the importance of the substantia nigra and Lewy bodies. In Stern G (Ed.) Parkinson’s disease, pp. 185–238, Chapman & Hall Medical, London, 1990

    Google Scholar 

  • Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 53: 96–101, 1990

    Article  CAS  Google Scholar 

  • Galea-Debono A, Marsden CD, Asselman P, Parkes JD. Bromocriptine and dopamine receptor stimulation. British Journal of Clinical Pharmacology 3: 977–982, 1976

    Article  Google Scholar 

  • Goetz CG, Tanner CM, Glantz RH, Klawans HL. Chronic agonist therapy for Parkinson’s disease: a five year study of bromocriptine and pergolide. Neurology 35: 749–751, 1985

    Article  PubMed  CAS  Google Scholar 

  • Goetz CG, Tanner CM, Shannon KM, Carroll VS, Klawans HL et al. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson’s disease patients with and without motor fluctuations. Neurology 38: 1143–1146, 1988

    Article  PubMed  CAS  Google Scholar 

  • Gopinathan G, Teravainen H, Dambrosia JM, Ward CD, Sanes JN, et al. Lisuride in parkinsonism. Neurology 31: 371–376, 1981

    PubMed  CAS  Google Scholar 

  • Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, et al. Dopamine D2 receptor density remains constant in treated Parkinson’s disease. Annals of Neurology 19: 487–492, 1986

    Article  PubMed  CAS  Google Scholar 

  • Hardie RJ, Lees AJ, Stern G. On-off fluctuations in Parkinson’s disease. Brain 107: 487–506, 1984

    Article  PubMed  Google Scholar 

  • Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467–469, 1984

    Article  PubMed  CAS  Google Scholar 

  • Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 17: 427–442, 1967

    Article  PubMed  CAS  Google Scholar 

  • Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacology Reviews 18: 925–964, 1966

    CAS  Google Scholar 

  • Horrocks PM, Vicary DJ, Rees JE, Parkes JD, Marsden CD. Anticholinergic withdrawal and benzhexol treatment in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 36: 936–941, 1973

    Article  CAS  Google Scholar 

  • Hughes RC, Polgar JG, Weightman D, Walton JN. Levodopa in parkinsonism: the effects of withdrawal of anticholinergic drugs. British Medical Journal 2: 487–491, 1971

    Article  PubMed  CAS  Google Scholar 

  • Jankovic J. Long-term study of pergolide in Parkinson’s disease. Neurology 35: 296–299, 1985

    Article  PubMed  CAS  Google Scholar 

  • Kurlan R, Miller C, Levy R, Macik B, Hamill R, et al. Long-term experience with pergolide therapy of advanced parkinsonism. Neurology 35: 738–742, 1985

    Article  PubMed  CAS  Google Scholar 

  • Langtry HD, Clissold SP. Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson’s disease. Drugs 39: 491–506, 1990

    Article  PubMed  CAS  Google Scholar 

  • Lees AJ. A sustained-release formulation of L-Dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson’s disease. European Neurology 27(Suppl. 1): 126–134, 1987

    Article  PubMed  Google Scholar 

  • Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry 44: 1020–1023, 1981

    Article  CAS  Google Scholar 

  • LeWitt PA, Gopinathan G, Ward CD, Sanes JN, Dambrosia JM, et al. Lisuride versus bromocriptine treatment in Parkinson’s disease: a double-blind study. Neurology 32: 69–72, 1982

    Article  PubMed  CAS  Google Scholar 

  • LeWitt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 33: 1009–1014, 1983

    Article  PubMed  CAS  Google Scholar 

  • Lieberman AN, Gopinathan G, Neophytides A, Leibowitz M, Walker R, et al. Bromocriptine and lisuride in Parkinson’s disease. Annals of Neurology 13: 44–47, 1983

    Article  PubMed  CAS  Google Scholar 

  • Lieberman AN, Kupersmith M, Casson I. Bromocriptine and lergotrile comparative efficacy in Parkinson’s disease. Advances in Neurology 24: 261–273, 1979

    Google Scholar 

  • Marsden CD, Parkes JD. On-off effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1: 292–296, 1976

    Article  PubMed  CAS  Google Scholar 

  • Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson’s disease: clinical aspects. In Marsden CD & Fahn S (Eds) Movement disorders, pp. 96–122, Butterworth, London, 1980

    Google Scholar 

  • Martin WE, Loewenson RB, Resch JA, Baker AB. A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson’s disease. Neurology 24: 912–919, 1974

    Article  PubMed  CAS  Google Scholar 

  • Mayeux R, Stern Y, Mulvey K, Cote L. Reappraisal of temporary levodopa withdrawal (’drug holiday’) in Parkinson’s disease. New England Journal of Medicine 313: 724–728, 1985

    Article  PubMed  CAS  Google Scholar 

  • Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Annals of Neurology 8: 558–563, 1980

    Article  PubMed  CAS  Google Scholar 

  • Narabayashi H, Kondo T, Nagatsu R. L-threo 3, 4-dihydroxyphenyl-serine treatment for freezing and akinesia in Parkinsonism. Neurology 32 (Suppl.): A180, 1982

    Article  Google Scholar 

  • Narabayashi H, Kondo T, Nagatsu T. DL-threo-3, 4-dihydroxyphenyl serine for freezing symptoms in Parkinsonism. Advances in Neurology 40: 498–502, 1984

    Google Scholar 

  • Nastuk WL, Su PC, Doubilet P. Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 264: 76–79, 1976

    Article  PubMed  CAS  Google Scholar 

  • Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clinical Neuropharmacology 7: 35–49, 1984

    Article  PubMed  CAS  Google Scholar 

  • Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The on-off phenomenon in Parkinson’s disease. New England Journal of Medicine 310: 483–488, 1984

    Article  PubMed  CAS  Google Scholar 

  • Obeso JA, Luquin MR, Martinez-Lage JM. Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1: 467–470, 1986

    Article  PubMed  CAS  Google Scholar 

  • Oldendorf WH. Brain uptake of radiolabeled amino acids and hexoses after arterial injection. American Journal of Physiology 221: 1629–1639, 1971

    PubMed  CAS  Google Scholar 

  • Parkes JD. Domperidone and Parkinson’s disease. Clinical Neuropharmacology 9: 517–532, 1986

    Article  PubMed  CAS  Google Scholar 

  • Parkes JD, Baxter RC, Marsden CD, Rees JE. Comparative trial of benzhexol, amantadine and levodopa in the treatment of Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychitary 37: 422–426, 1974

    Article  CAS  Google Scholar 

  • Parkes JD, Schachter M, Marsden CD, Smith B, Wilson A. Lisuride in parkinsonism. Annals of Neurology 9: 48–52, 1981

    Article  PubMed  CAS  Google Scholar 

  • Poewe WH, Lees AJ, Stern GM. Treatment of motor fluctuations in Parkinson’s disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clinical Neuropharmacology 9: 430–439, 1986

    Article  PubMed  CAS  Google Scholar 

  • Quinn NP, Critchley P, Marsden CD. Young onset Parkinson’s disease. Movement Disorders 2: 73–91, 1987

    Article  PubMed  CAS  Google Scholar 

  • Quinn NP, Parkes JD, Marsden CD. Control of on-off phenomenon by continuous intravenous infusion of levodopa. Neurology 34: 1131–1136, 1984

    Article  PubMed  CAS  Google Scholar 

  • Rascol A, Monastruc JL, Guiraud-Chaumeil B, Clanet M. Bromocriptine as the first treatment of Parkinson’s disease. Long-term results. Revue Neurologique (Paris) 138: 401–408, 1982

    CAS  Google Scholar 

  • Rinne UK. Early combination of bromocriptine and levodopa in the Treatment of Parkinson’s disease: a 5-year follow-up. Neurology 37: 826–828, 1987

    Article  PubMed  CAS  Google Scholar 

  • Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 39: 336–339, 1989

    Article  PubMed  CAS  Google Scholar 

  • Sage JI, Mark MH. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson’s disease: a double-blind crossover study. Clinical Neuropharmacology 11: 174–179, 1988

    Article  PubMed  CAS  Google Scholar 

  • Sage JI, Schuh L, Heikkila RE, Duvoisin RC. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson’s disease. Clinical Neuropharmacology 11: 36–44, 1988

    Article  PubMed  CAS  Google Scholar 

  • Schwab RS, Amadori LV, Lettvin JY. Apomorphine in Parkinson’s Disease. Transactions of the American Neurological Association 76: 251–253, 1951

    Google Scholar 

  • Schwab RS, England AC, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s disease. Journal of the American Medical Association 208: 1168–1170, 1969

    Article  PubMed  CAS  Google Scholar 

  • Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson’s disease. Quarterly Journal of Medicine 49: 283–293, 1980

    PubMed  CAS  Google Scholar 

  • Shealy CN, Weeth JB, Mercier D. Livedo reticularis in patients with parkinsonism receiving amantadine. Journal of the American Medical Association 212: 1522–1523, 1970

    Article  PubMed  CAS  Google Scholar 

  • Shoulson I and the Parkinson Study Group. DATATOP: a multicentre controlled clinical trial in early Parkinson’s disease. Archives of Neurology 46: 1052–1060, 1989a

    Article  Google Scholar 

  • Shoulson I and the Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. New England Journal of Medicine 321: 1364–1371, 1989b

    Article  Google Scholar 

  • Stromberg U, Svensson TH. Further studies on the mode of action of amantadine. Acta Pharmacologica et Toxicologica 30: 161–171, 1971

    Article  PubMed  CAS  Google Scholar 

  • Sweet RD, Lee JE, Spiegel HE, McDowell F. Enhanced response to low doses of levodopa after withdrawal from chronic treatment. Neurology 22: 520–525, 1972

    Article  PubMed  CAS  Google Scholar 

  • Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 245: 519–522, 1989

    Article  PubMed  CAS  Google Scholar 

  • Von Voigtlander PF, Moore KE. Dopamine: Release from the brain in vivo by amantadine. Science 174: 408–410, 1971

    Article  Google Scholar 

  • Wade LA, Katzman R. Synthetic amino acids and the nature of L-dopa transport at the blood-brain barrier. Journal of Neurochemistry 25: 837–842, 1975

    Article  PubMed  CAS  Google Scholar 

  • Walters EC, Hurwitz TA, Mak E, Teal P, Peppard FR, et al. Clozapine in the treatment of parkinsonian pateints with dopaminomimetic psychosis. Neurology 40: 832–834, 1990

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, St James’s University Hospital, Beckett Street, Leeds, LS9 7TF, England

    R. J. Coleman

Authors
  1. R. J. Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coleman, R.J. Current Drug Therapy for Parkinson’s Disease. Drugs & Aging 2, 112–124 (1992). https://doi.org/10.2165/00002512-199202020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199202020-00005

Keywords

Search

Navigation